Clinical trials: Clostridioides Difficile Infection Recurrence

Clostridium Difficile Infection Recurrence, Clostridium Difficile Infection

Phase 2 Study of VE303 for Prevention of Recurrent Clostridioides Difficile Infection

• Completed
• Age: 18 years and older
• Phase 2
• Pill or oral medicine
• Results posted

This study evaluated the safety and efficacy of VE303 for participants with primary C. difficile infection (pCDI) at high risk for recurrence or subjects with recurrent C. difficile infections (rCDI).

Conditions

Clostridium Difficile Infection Recurrence, Clostridium Difficile Infection, Clostridium Difficile, Clostridioides Difficile Infection Recurrence

Trial name

CONSORTIUM (NCT03788434)

Testing

VE303

Where

37 sites in United States, Canada

Volunteers

79 people

Sponsor

Vedanta Biosciences, Inc.